Compare $PVLA vs $VRDN | Chartloom

Compare

$PVLA vs $VRDN

Palvella Therapeutics Inc · Viridian Therapeutics Inc

PVLA

Palvella Therapeutics Inc

VRDN

Viridian Therapeutics Inc

Compare $PVLA vs $VRDN

Comparing Palvella Therapeutics Inc and Viridian Therapeutics Inc

PVLAPalvella Therapeutics Inc

VRDNViridian Therapeutics Inc

PVLAPalvella Therapeutics Inc

Market cap

$1.99B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-97.2%

YTD performance

38.4%

52W performance

85.4%

FCF yield

-1.8%

VRDNViridian Therapeutics Inc

Market cap

$2.06B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

14.59x

Rev growth (TTM)

23220.3%

YTD performance

-39.2%

52W performance

-12.6%

FCF yield

-16.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

PVLA

VRDN

Detailed metrics comparison

PVLA

Palvella Therapeutics Inc

VRDN

Viridian Therapeutics Inc

Market Cap

PVLA$1.99B

VRDN$2.06B

Enterprise Value

PVLA$1.82B

VRDN$2.25B

Price

PVLA$138.77

VRDN$18.66

P/E Ratio

PVLAN/A

VRDNN/A

P/S Ratio

PVLA46.64x

VRDN28.97x

EV/Sales

PVLA0.00x

VRDN31.65x

EV/EBITDA

PVLA0.00x

VRDN0.00x

P/B Ratio

PVLA8.80x

VRDN3.58x

P/FCF Ratio

PVLAN/A

VRDNN/A

EV/FCF

PVLA-49.96x

VRDN-6.72x

PEG Ratio

PVLAN/A

VRDNN/A

Forward P/E (NTM)

PVLAN/A

VRDNN/A

Forward P/S (NTM)

PVLAN/A

VRDN14.59x

Revenue (TTM)

PVLA$0

VRDN$71M

Revenue Growth (YoY)

PVLA-97.2%

VRDN23220.3%

Forward Rev Growth

PVLA287.4%

VRDN729.0%

Gross Margin (TTM)

PVLA0.0%

VRDN2.4%

Operating Margin (TTM)

PVLA0.0%

VRDN0.0%

EBITDA Margin (TTM)

PVLA0.0%

VRDN-569.0%

Net Margin (TTM)

PVLA0.0%

VRDN-544.1%

FCF Margin (TTM)

PVLAN/A

VRDN-471.0%

Net Income (TTM)

PVLA$-62M

VRDN$-387M

FCF (TTM)

PVLA$-37M

VRDN$-335M

EPS (TTM)

PVLA-$4.30

VRDN-$3.59

ROE (TTM)

PVLA-4784.0%

VRDN-6135.0%

ROA (TTM)

PVLA-3833.0%

VRDN-4603.0%

ROIC (TTM)

PVLA-4172.0%

VRDN-5041.0%

Cash

PVLA$188M

VRDN$165M

Debt

PVLA$22M

VRDN$356M

Net Cash/Debt

PVLA$166M

VRDN$-191M

Current Ratio (TTM)

PVLA21.18x

VRDN16.95x

Quick Ratio (TTM)

PVLA21.01x

VRDN16.56x

Debt/Equity (TTM)

PVLA0.10x

VRDN0.54x

Debt/Assets (TTM)

PVLA0.0%

VRDN0.0%

Interest Coverage (TTM)

PVLAN/A

VRDNN/A

Net Debt/EBITDA (TTM)

PVLA0.00x

VRDN0.00x

Beta

PVLA-0.19

VRDN1.11

52W Performance

PVLA85.4%

VRDN-12.6%

YTD Performance

PVLA38.4%

VRDN-39.2%

% from 52W High

PVLA-14.0%

VRDN-45.6%

% from 52W Low

PVLA110.5%

VRDN41.6%

Asset Turnover (TTM)

PVLA0.76x

VRDN0.08x

FCF Yield (TTM)

PVLA-1.8%

VRDN-16.3%

Earnings Yield (TTM)

PVLA-3.1%

VRDN-18.8%

Dividend Yield (TTM)

PVLAN/A

VRDNN/A

Rule of 40

PVLA-97.2

VRDN22,749.3

EV/GP/RG

PVLAN/A

VRDN8.67

Ticker research

View PVLA research View VRDN research

Metric	PVLA Palvella Therapeutics Inc	VRDN Viridian Therapeutics Inc
Market & Valuation
Market Cap	$1.99B	$2.06B
Enterprise Value	$1.82B	$2.25B
Price	$138.77	$18.66
P/E Ratio	N/A	N/A
P/S Ratio	46.64x	28.97x
EV/Sales	0.00x	31.65x
EV/EBITDA	0.00x	0.00x
P/B Ratio	8.80x	3.58x
P/FCF Ratio	N/A	N/A
EV/FCF	-49.96x	-6.72x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	14.59x
Revenue & Growth
Revenue (TTM)	$0	$71M
Revenue Growth (YoY)	-97.2%	23220.3%
Forward Rev Growth	287.4%	729.0%
Profitability
Gross Margin (TTM)	0.0%	2.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-569.0%
Net Margin (TTM)	0.0%	-544.1%
FCF Margin (TTM)	N/A	-471.0%
Net Income (TTM)	$-62M	$-387M
FCF (TTM)	$-37M	$-335M
EPS (TTM)	-$4.30	-$3.59
ROE (TTM)	-4784.0%	-6135.0%
ROA (TTM)	-3833.0%	-4603.0%
ROIC (TTM)	-4172.0%	-5041.0%
Financial Health
Cash	$188M	$165M
Debt	$22M	$356M
Net Cash/Debt	$166M	$-191M
Current Ratio (TTM)	21.18x	16.95x
Quick Ratio (TTM)	21.01x	16.56x
Debt/Equity (TTM)	0.10x	0.54x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.19	1.11
52W Performance	85.4%	-12.6%
YTD Performance	38.4%	-39.2%
% from 52W High	-14.0%	-45.6%
% from 52W Low	110.5%	41.6%
Efficiency & Yields
Asset Turnover (TTM)	0.76x	0.08x
FCF Yield (TTM)	-1.8%	-16.3%
Earnings Yield (TTM)	-3.1%	-18.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-97.2	22,749.3
EV/GP/RG	N/A	8.67
Ticker research	View PVLA research	View VRDN research

Valuation

P/S Ratio

VRDN

28.97x

PVLA

46.64x

EV/FCF

PVLA

-49.96x

VRDN

-6.72x

Growth & revenue

Revenue Growth TTM

VRDN

23220.3%

PVLA

-97.2%

Forward Revenue Growth

VRDN

729.0%

PVLA

287.4%

Profitability & performance

Gross Margin

VRDN

2.4%

PVLA

0.0%

ROE

PVLA

-4784.0%

VRDN

-6135.0%

FCF Yield %

PVLA

-1.8%

VRDN

-16.3%

52-Week Performance

PVLA

85.4%

VRDN

-12.6%

Detailed metrics comparison

PVLA

Palvella Therapeutics Inc

VRDN

Viridian Therapeutics Inc

Market Cap

PVLA$1.99B

VRDN$2.06B

Enterprise Value

PVLA$1.82B

VRDN$2.25B

Price

PVLA$138.77

VRDN$18.66

P/E Ratio

PVLAN/A

VRDNN/A

P/S Ratio

PVLA46.64x

VRDN28.97x

EV/Sales

PVLA0.00x

VRDN31.65x

EV/EBITDA

PVLA0.00x

VRDN0.00x

P/B Ratio

PVLA8.80x

VRDN3.58x

P/FCF Ratio

PVLAN/A

VRDNN/A

EV/FCF

PVLA-49.96x

VRDN-6.72x

PEG Ratio

PVLAN/A

VRDNN/A

Forward P/E (NTM)

PVLAN/A

VRDNN/A

Forward P/S (NTM)

PVLAN/A

VRDN14.59x

Revenue (TTM)

PVLA$0

VRDN$71M

Revenue Growth (YoY)

PVLA-97.2%

VRDN23220.3%

Forward Rev Growth

PVLA287.4%

VRDN729.0%

Gross Margin (TTM)

PVLA0.0%

VRDN2.4%

Operating Margin (TTM)

PVLA0.0%

VRDN0.0%

EBITDA Margin (TTM)

PVLA0.0%

VRDN-569.0%

Net Margin (TTM)

PVLA0.0%

VRDN-544.1%

FCF Margin (TTM)

PVLAN/A

VRDN-471.0%

Net Income (TTM)

PVLA$-62M

VRDN$-387M

FCF (TTM)

PVLA$-37M

VRDN$-335M

EPS (TTM)

PVLA-$4.30

VRDN-$3.59

ROE (TTM)

PVLA-4784.0%

VRDN-6135.0%

ROA (TTM)

PVLA-3833.0%

VRDN-4603.0%

ROIC (TTM)

PVLA-4172.0%

VRDN-5041.0%

Cash

PVLA$188M

VRDN$165M

Debt

PVLA$22M

VRDN$356M

Net Cash/Debt

PVLA$166M

VRDN$-191M

Current Ratio (TTM)

PVLA21.18x

VRDN16.95x

Quick Ratio (TTM)

PVLA21.01x

VRDN16.56x

Debt/Equity (TTM)

PVLA0.10x

VRDN0.54x

Debt/Assets (TTM)

PVLA0.0%

VRDN0.0%

Interest Coverage (TTM)

PVLAN/A

VRDNN/A

Net Debt/EBITDA (TTM)

PVLA0.00x

VRDN0.00x

Beta

PVLA-0.19

VRDN1.11

52W Performance

PVLA85.4%

VRDN-12.6%

YTD Performance

PVLA38.4%

VRDN-39.2%

% from 52W High

PVLA-14.0%

VRDN-45.6%

% from 52W Low

PVLA110.5%

VRDN41.6%

Asset Turnover (TTM)

PVLA0.76x

VRDN0.08x

FCF Yield (TTM)

PVLA-1.8%

VRDN-16.3%

Earnings Yield (TTM)

PVLA-3.1%

VRDN-18.8%

Dividend Yield (TTM)

PVLAN/A

VRDNN/A

Rule of 40

PVLA-97.2

VRDN22,749.3

EV/GP/RG

PVLAN/A

VRDN8.67

Ticker research

View PVLA research View VRDN research

Metric	PVLA Palvella Therapeutics Inc	VRDN Viridian Therapeutics Inc
Market & Valuation
Market Cap	$1.99B	$2.06B
Enterprise Value	$1.82B	$2.25B
Price	$138.77	$18.66
P/E Ratio	N/A	N/A
P/S Ratio	46.64x	28.97x
EV/Sales	0.00x	31.65x
EV/EBITDA	0.00x	0.00x
P/B Ratio	8.80x	3.58x
P/FCF Ratio	N/A	N/A
EV/FCF	-49.96x	-6.72x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	14.59x
Revenue & Growth
Revenue (TTM)	$0	$71M
Revenue Growth (YoY)	-97.2%	23220.3%
Forward Rev Growth	287.4%	729.0%
Profitability
Gross Margin (TTM)	0.0%	2.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-569.0%
Net Margin (TTM)	0.0%	-544.1%
FCF Margin (TTM)	N/A	-471.0%
Net Income (TTM)	$-62M	$-387M
FCF (TTM)	$-37M	$-335M
EPS (TTM)	-$4.30	-$3.59
ROE (TTM)	-4784.0%	-6135.0%
ROA (TTM)	-3833.0%	-4603.0%
ROIC (TTM)	-4172.0%	-5041.0%
Financial Health
Cash	$188M	$165M
Debt	$22M	$356M
Net Cash/Debt	$166M	$-191M
Current Ratio (TTM)	21.18x	16.95x
Quick Ratio (TTM)	21.01x	16.56x
Debt/Equity (TTM)	0.10x	0.54x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.19	1.11
52W Performance	85.4%	-12.6%
YTD Performance	38.4%	-39.2%
% from 52W High	-14.0%	-45.6%
% from 52W Low	110.5%	41.6%
Efficiency & Yields
Asset Turnover (TTM)	0.76x	0.08x
FCF Yield (TTM)	-1.8%	-16.3%
Earnings Yield (TTM)	-3.1%	-18.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-97.2	22,749.3
EV/GP/RG	N/A	8.67
Ticker research	View PVLA research	View VRDN research